多索茶碱联合头孢他啶治疗慢性阻塞性肺疾病急性加重期临床观察

Clinical observation of doxofylline combined with ceftazidime in the treatment of acute exacerbation of chronic obstructive pulmonary disease

目的:探讨慢性阻塞性肺疾病急性加重期采取多索茶碱联合头孢他啶治疗的疗效。方法:选取2015年5月至2016年5月期间我院接收治的68例慢性阻塞性肺疾病急性加重期患者,随机分为对照组(n=34,予以头孢他啶治疗)与观察组(n=34,予以多索茶碱联合头孢他啶治疗),两组均给予吸氧、补液、营养支持等常规治疗,对两组患者疗效进行观察比较。结果:观察组患者临床治疗有效率94. 1%,明显高于对照组76. 5%,差异有统计学意义(P <0. 05);观察组患者的肺功能指标高于对照组,差异有统计学意义(P <0. 05);观察组患者SF-36评分高于对照组,差异有统计学意义(P <0. 05);观察组不良反应发生率为14. 71%,对照组为17. 65%,2组比较差异无统计学有意义(P> 0. 05)。结论:慢性阻塞性肺疾病急性加重期采取多索茶碱联合头孢他啶治疗效果显著,无明显不良反应,有临床推广价值。

Objective:To investigate the efficacy of doxofylline combined with ceftazidime in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods:68 patients with chronic obstructive pulmonary disease admitted to our hospital from May 2015 to May 2016 were randomly divided into control group (n=34,treated with ceftazidime) and observation group (n=34,treated with doxofylline and ceftazidime).Both groups were given routine treatment such as oxygen inhalation,fluid replacement and nutritional support.The curative effect of the two groups was observed and compared.Results:The effective rate of clinical treatment in the observation group was 94.1%,significantly higher than 76.5% in the control group,with statistical significance (P<0.05);the pulmonary function index in the observation group was higher than that in the control group,with statistical significance (P<0.05);the SF-36 score in the observation group was higher than that in the control group,with statistical significance (P<0.05);the incidence of adverse reactions in the observation group was 14.71%,and that in the control group was 17.65%.There was no significant difference between the two groups (P>0.05).Conclusion:Doxofylline combined with ceftazidime in the treatment of acute exacerbation of chronic obstructive pulmonary disease is effective,without obvious adverse reactions,and has clinical popularization value.